000			03422nam a22003855i 4500
001			81900
003			ES-MaUEC
005			20230207040345.0
007			cr nn 008mamaa
008			141129s2015 xxk| s |||| 0|eng d
020			_a9781447149200
024	7		_a10.1007/978-1-4471-4920-0 _2doi
050		4	_aRM301.25 _b2015 EB
245	1	0	_aTranslational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development : _bA Focus on Early Phase Clinical Studies _cedited by Andrew J. Krentz, Lutz Heinemann, Marcus Hompesch.
260			_aLondon _bSpringer _c2015
300			_a1 recurso en línea (XII, 312 páginas) _b76 ilustraciones, 39 ilustraciones en color
336			_aTexto _btxt _2rdacontent
337			_aelectrónico _bc _2rdamedia
338			_arecurso electrónico _bcr _2rdacarrier
505	0		_a1. Review of physiology/pathophysiology -- 2. Methods for assessing insulin action in humans -- 3. Assessment of insulin secretion -- 4. Measurement of ectopic fat in liver and muscle using magnetic resonance spectroscopy -- 5. Isotopic tracers for theÂ{uD961}surement of metabolic flux -- 6. Measuring food intake inÂ{u3B29}nical drug development -- 7. Measurement of energy expenditure -- 8. Assessment of body composition -- 9.Â{u0073}sessment of cardiovascular safety of new diabetes drugs.
520	3		_aThis book aims to aid the selection of the most appropriate techniques for use in earlyÂ{u0A21}se (1 and 2) clinicalÂ{u3D35}dies of new drugs for diabetes, obesity, and related cardiometabolic disease. Clinical research methods for assessing theÂ{u0A21}rmacokinetics and pharmacodynamics of new diabetes drugs, e.g. the euglycaemicÂ{u3B21}mp technique,Â{u8876}e become well-established in proof-of-mechanism studies; however, selection of the best techniques is by no means straightforward. This bookÂ{u7A6C}lÂ{u1A64} the understanding ofÂ{u4A25} needÂ{u6BF2} newÂ{u0A21}rmacotherapiesÂ{u6BF2}Â{u4E70}e 1 diabetes, type 2 diabetes, and obesity and the molecular targets of drugs currently in development.Â{u2805}EmergingÂ{u4963}hnologies including the omics disciplinesÂ{u1CA5} considered togetherÂ{u7A74}h practical and ethicalÂ{u9CF3}ues ofÂ{u5872}ly phase clinicalÂ{u4CA9}als in subjects with cardiometabolic disorders. Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug DevelopmentÂ{u2837}will be of interest to biomedical scientists, pharmacologists, academics involved in metabolic research and clinicians practicing in these specialties.
710	2		_aSpringerLink (Online service) _0Local _9106996
942			_2lcc _cLE
650		7	_aTecnología farmacéutica _2embne _9161127
650		7	_aDiabetes. _9138582 _2embne
650		7	_aFarmacología _2embne _9137893
700	1		_aKrentz, Andrew J. _eeditor literario _0Local _994432
700	1		_aHeinemann, Lutz _eeditor literario _994433 _0Local
700	1		_aHompesch, Marcus _eeditor literario _994434 _0Local
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://link.springer.com/book/10.1007/978-1-4471-4920-0 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
907			_a.b12905392 _b10-10-17 _c10-02-16
988			_aSpringer_Medicine_2015
998			_am _a_alco _a_vill _b - - _cm _dz _e- _feng _gxxk _h0
945			_aRM301.25 T736 2015 EB _g1 _ieBOOK _j0 _lmae _o- _pEUR0.00 _q- _r- _sb _t15 _u0 _v0 _w0 _x0 _y.i11573089 _z06-04-17
999			_c81900 _d81900 _x1